Hippeastrum mirum

Mirum Pharmaceuticals Presents New Data at The Liver Meeting®

Retrieved on: 
Monday, November 13, 2023
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Sleep, Hepatology, MDR3, Self-harm, Safety, Hepatocellular carcinoma, Bilirubin, Cholestasis, AASLD, Liver, Disease, Risk, Cholestatic pruritus, Hematology, Quality of life (healthcare), MYO5B, PFIC, Patient, Publication, Pregnancy, Nature, TJP2, Ascending cholangitis, GI, Hippeastrum mirum, Liver support system, Volixibat, ICP, IBAT, Progressive familial intrahepatic cholestasis, FIC, Augmented fifth, Growth, Doctor of Philosophy, Quality of life, AND, Itch, Medication, MCID, HIV disease progression rates, SBA, Chloride, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, Boston, BSEP

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced new data from its LIVMARLI and volixibat programs presented at The Liver Meeting®, the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, Massachusetts.
  • “PFIC is a chronic, debilitating cholestatic liver disease characterized by elevated bile acids and pruritus so severe that patients can be listed for liver transplant even in the absence of disease progression.
  • These data suggest overall improved liver health with maralixibat treatment in patients with PFIC that can be maintained long-term.
  • No clinically meaningful changes in liver enzyme levels or hematology parameters were observed after volixibat treatment.

Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN

Retrieved on: 
Saturday, October 7, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Hypercholesterolemia, Doctor of Philosophy, Food, ALGS, Bile, Safety, SBA, Hippeastrum mirum, Xanthoma, Cholestatic pruritus, FDA, Poster, Maintenance, Itch, Clinical trial, Publication, Alagille syndrome, Sleep, PFIC, Medication, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RISE, Bilirubin, Patient, Quality of life, Pharmaceutical industry, Dietary supplement, Nursing

Data presented during NASPGHAN demonstrated continued evidence of the impact of LIVMARLI for patients with PFIC as well as both clinical data and real-world use of LIVMARLI in patients with ALGS.

Key Points: 
  • Data presented during NASPGHAN demonstrated continued evidence of the impact of LIVMARLI for patients with PFIC as well as both clinical data and real-world use of LIVMARLI in patients with ALGS.
  • Presentations included:
    Data from the MARCH PFIC Phase 3 Study was awarded the prestigious Gerard Odell prize for Excellence in Pediatric Hepatology Research.
  • The MARCH PFIC clinical trial was conducted across the broadest range of PFIC types ever studied.
  • Real-world data in patients with ALGS was presented on adherence to LIVMARLI as well as reduction of other medications and vitamin supplementation while on LIVMARLI.

Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress

Retrieved on: 
Friday, June 23, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Chloride, ALGS, Maintenance, EASL, Hippeastrum mirum, Cholestasis, SBA, Sleep, Research, Doctor of Philosophy, MRX, Medication, Congress, HIV disease progression rates, Patient, Concentration ratio, Bilirubin, Itch, Progressive familial intrahepatic cholestasis, IBAT, Alagille syndrome, Ageing, European Association for the Study of the Liver, PFIC, Safety, Pharmaceutical industry, Medical imaging, Fertilizer, Surveying, Toy, Liver

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria.
  • The congress presentations feature new analyses from the LIVMARLI® (maralixibat) oral solution MARCH-PFIC study as well as the long-term extension study, MARCH-ON.
  • Additionally, data showing LIVMARLI’s benefit in adult patients with Alagille syndrome (ALGS) was presented during EASL.
  • All presentations are available in the Publications and Presentations section on Mirum’s website.

Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting

Retrieved on: 
Friday, May 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, CXS, Hippeastrum mirum, CET, SBA, Cholesterol, Research, Publication, AdventHealth, Doctor of Philosophy, Medication, Xanthoma, Hypercholesterolemia, Professor, Patient, Fracture, Augmented fifth, Itch, Bilirubin, Annual general meeting, Bile, Gastrointestinal bleeding, International Society for Pediatric and Adolescent Diabetes, Liver, Poster, IBAT, Alagille syndrome, GI, PFIC, Cholestatic pruritus, Safety, Pharmaceutical industry, Nightclub, Dietary supplement, ALGS, Nutrition, Gastroenterology

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting.

Key Points: 
  • Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the 55th European Society for Pediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting.
  • Among the data presented were four oral and three poster presentations featuring analyses from LIVMARLI® (maralixibat) oral solution clinical studies.
  • The analysis evaluated the impact of LIVMARLI on xanthomas using data from ALGS studies.
  • The data showed that LIVMARLI was well-tolerated in a real-world setting with lower rates of adverse events than described in clinical trials.

Adiso Therapeutics Announces the Appointment of Srikar Guntaka, M.D., as Medical Director

Retrieved on: 
Thursday, February 9, 2023
Medical director, AbbVie, Ulcerative colitis, Therapy, Nandini Srikar, LS, Patient, Drug, Hippeastrum mirum, Pharmacovigilance, Inflammation, Baxter International, Pharmaceutical industry, Gastroenterology

CONCORD, Mass., Feb. 9, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, has appointed Srikar Guntaka, M.D., as its Medical Director.

Key Points: 
  • CONCORD, Mass., Feb. 9, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, has appointed Srikar Guntaka, M.D., as its Medical Director.
  • Most recently Dr. Srikar served as Medical Director, Clinical Development lead at Mirum Pharmaceuticals leading all aspects of global development for multiple indications of volixibat in adults.
  • "We are excited to welcome Srikar during this critical period for the company and our pipeline," said Adiso CEO Scott Megaffin.
  • Prior to Adiso and Mirum, he was Associate Medical Director, Gastroenterology (US Medical Affairs) at Abbvie where he provided strategic and operational input into core medical affairs activities.